Definium Therapeutics, Inc. (DFTX) Stock Price & Analysis

Definium Therapeutics, Inc. (DFTX) rose 1.73% to USD 38.75 as of September 8, 2026 at 17:04 UTC, according to Nexqual real-time market data.

DFTX last closed at USD 38.75; the session ranged USD 37.7–39.22 on volume of 769,615 shares. Market capitalization is —, with a 52-week range of USD 8.77–49.7 (NMS). Source: Nexqual, September 8, 2026 at 17:04 UTC.

Key Statistics (as of September 8, 2026 at 17:04 UTC)

Technical Analysis (DFTX)

Nexqual's technical model rates DFTX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 17:04 UTC.

From Definium Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our patent portfolio, as of February 19, 2026, contains 12 issued U.S. patents, 29 pending U.S. applications, and 1 pending patent cooperation treaty application that are either solely owned by us or in-licensed, as well as certain foreign counterparts of a subset of these patent applications in foreign countries, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Singapore, South Korea, and Taiwan.
• Intra-Cellular Therapies, now a part of J&J ("Intra-Cellular"), is currently developing multiple product candidates that are in various phases of development for the treatment of GAD and MDD, including CAPLYTA (lumateperone), which was approved by the FDA in November 2025 as an adjunctive treatment for adults with MDD, and ITI-1284 ODT-SL for GAD.
• IND Application An IND is a request for authorization from the FDA to administer an investigational drug product to humans.
• Our second lead product candidate, DT402 (previously referred to as MM402), also referred to as R(-)-MDMA, is our proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine ("MDMA"), which we are developing for the treatment of adults with autism spectrum disorder ("ASD").

Partnerships

• Catalent In August 2023, we announced an exclusive licensing agreement with Catalent for its patented Zydis® ODT technology.
• Research Collaborations On April 1, 2020, we entered into a multi-year, exclusive collaboration with Dr.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 17:04 UTC. This page is informational and not investment advice.